Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Reardon, D A, Herndon, J E, Peters, K B, Desjardins, A, Coan, A, Lou, E, Sumrall, A L, Turner, S, Lipp, E S, Sathornsumetee, S, Rich, J N, Sampson, J H, Friedman, A H, Boulton, S T, Bigner, D D, Friedman, H S, Vredenburgh, J J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493761/
https://www.ncbi.nlm.nih.gov/pubmed/23037712
http://dx.doi.org/10.1038/bjc.2012.415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493761/
https://www.ncbi.nlm.nih.gov/pubmed/23037712
http://dx.doi.org/10.1038/bjc.2012.415

Ejemplares similares